Oric Pharmaceuticals, Inc. ORIC 深 沪
已收盘 09-18 16:00:00 美东时间
12.79
-0.090
-0.70%
华盛通- 最 高12.91
- 今 开12.81
- 成交量 309.09万股
- 最 低 12.475
- 昨 收 12.88
- 总市值 13.26亿
- 52周最高 14.93
- 市盈率 静 --
- 换手率 2.98%
- 52周最低 7.23
- 委 比 -7.32%
- 总股本 1.04亿
- 历史最高 40.81
- 量 比 2.06
- 振 幅 3.38%
- 历史最低 2.36
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
08-10 19:58
美股牛股 | 绩优股齐升！Palantir大涨逾29%，Q2营收强劲增长并上调全年指引；Wayfair飙升30%，Corvex涨逾27%
绩优股齐升！Palantir大涨逾29%，Q2营收暴增93%并上调全年指引；Wayfair飙升30%，Q2业绩全面超预期；Corvex涨逾27%，斩获AI巨头Blackwell供应协议>>
08-05 19:24
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share from the same period last year.
08-04 04:57
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 400 points on Monday. Shares of Bandwidth Inc (NASDAQ:BAND) fell sharply in pre-market trading after the company announced a proposed private offering of $275 million of convertible senior notes. Bandwidth shares dip...
06-15 20:01
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
06-08 18:24
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
05-05 23:54
ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster
04-18 04:07
